Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation.
about
Transcription factors in late megakaryopoiesis and related platelet disordersDasatinib accelerates valproic acid-induced acute myeloid leukemia cell death by regulation of differentiation capacityMegakaryocyte-specific deletion of the protein-tyrosine phosphatases Shp1 and Shp2 causes abnormal megakaryocyte development, platelet production, and function.Mice lacking the ITIM-containing receptor G6b-B exhibit macrothrombocytopenia and aberrant platelet functionA Src family kinase-Shp2 axis controls RUNX1 activity in megakaryocyte and T-lymphocyte differentiation.Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.Loss of the F-BAR protein CIP4 reduces platelet production by impairing membrane-cytoskeleton remodelingRecurrent Gastrointestinal Hemorrhage in Treatment with Dasatinib in a Patient Showing SMAD4 Mutation with Acute Lymphoblastic Leukemia Philadelphia Positive and Juvenile Polyposis Hereditary Hemorrhagic Telangiectasia Syndrome.Impaired proplatelet formation in immune thrombocytopenia: a novel mechanism contributing to decreased platelet count.Spontaneous subdural hematoma in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia with normal platelet count after dasatinib treatment.Gastrointestinal bleeding in a chronic myeloid leukaemia patient precipitated by dasatinib-induced platelet dysfunction: Case report.Lineage tracing of Pf4-Cre marks hematopoietic stem cells and their progeny.The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear.Crosstalk between NOTCH and AKT signaling during murine megakaryocyte lineage specificationPerspective: Tyrosine phosphatases as novel targets for antiplatelet therapy.Microfluidic whole blood testing of platelet response to pharmacological agents.JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia.Src family kinases: at the forefront of platelet activationTyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.Monitoring Cell-surface N-Glycoproteome Dynamics by Quantitative Proteomics Reveals Mechanistic Insights into Macrophage Differentiation.Dasatinib inhibits proinflammatory functions of mature human neutrophilsTyrosyl phosphorylation toggles a Runx1 switch.Dasatinib inhibits primary melanoma cell proliferation through morphology-dependent disruption of Src-ERK signaling.The cell division control protein 42-Src family kinase-neural Wiskott-Aldrich syndrome protein pathway regulates human proplatelet formation.PDK1 governs thromboxane generation and thrombosis in platelets by regulating activation of Raf1 in the MAPK pathway.Imaging platelet biogenesis in vivoTyrosine Kinase Inhibitor Pazopanib Inhibits Platelet Procoagulant Activity in Renal Cell Carcinoma Patients
P2860
Q27015841-7F2A0B9E-1B1E-418E-866B-146D7C66B458Q28539582-7F8F6D65-B09B-41FD-AA21-30B33A0FE177Q28587122-1518B606-2EE6-4C51-B9D7-D7C07056AAADQ28592055-09C26EBA-3ECD-43D7-A33F-141DBCF9D3A4Q32884462-05149896-E6E6-4B08-8E65-C2588349BB53Q33401360-C824CC90-D2A9-4526-8701-F5BB8F64CF11Q33409315-96F99803-2E2A-470F-B80B-A4D4DF8554F2Q33409349-46332428-70B1-4C69-9967-A90B6CBE1943Q33414241-6FF41871-39F6-4D28-9BEC-DE06302A3525Q33416438-436D7898-BD19-4F5A-BE48-955F5E0163D4Q33423255-5EAB7984-49F5-43E7-80F0-9B74A11FEFA0Q34540132-88FF10FC-BE19-4451-AAD0-1908A3DE0FDDQ34748167-7D7B9D61-8972-4D50-A465-A1D92DC66F7EQ35153770-E23A16BD-C6F9-413E-9915-AAEC777F8909Q35671956-16E5E6C7-AAF5-4E8D-AFB7-AAC1295A4AE3Q36253661-B01F5C36-BED8-4D4C-B94D-89712DA1F3F4Q37349414-174BE10C-4864-4A5B-8D9D-B070F2204B55Q38239258-5394C1ED-BB58-4470-BE72-A7F4DCBDDE51Q38457554-453B2817-9388-4FD0-9140-06604D267473Q38710906-E99A70BF-7662-41E0-A35E-24EE9813E5BAQ41885572-19F1059B-7806-4D37-95BA-9747A2048D1EQ42248791-376A77DA-73A2-4B37-8418-B1EA3E78A432Q43247067-87C89447-1652-47D0-B126-DFD70DC5185BQ49021516-0F762CA9-4E6C-4490-AD14-914DA1C13DAAQ54119484-6E286817-44B4-4921-95F7-7B6675E65D2CQ56990409-7414F273-E0A6-40CC-92B2-A32E3A0617DDQ59136392-7F1C4EB6-E18C-459B-8BD3-6139EF5620E5
P2860
Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation.
@ast
Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation.
@en
type
label
Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation.
@ast
Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation.
@en
prefLabel
Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation.
@ast
Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation.
@en
P2860
P50
P1433
P1476
Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation.
@en
P2093
Steffen Massberg
P2860
P304
P356
10.1182/BLOOD-2010-12-326850
P407
P577
2011-03-08T00:00:00Z